检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:柴宇飞 康凯[1] 赵德强[1] CHAI Yu-fei;KANG Kai;ZHAO De-qiang(Tieling Central Hospital,Liaoning Tieling 112000)
出 处:《中国医疗器械信息》2020年第13期104-105,共2页China Medical Device Information
摘 要:目的:研究应用显微镜下脑膜瘤切除术治疗中央回区脑膜瘤的效果。方法:研究样本选取时间为2017年6月~2018年4月,研究对象为于本院接受治疗中央回区脑膜瘤患者,共计38例。按照患者就诊先后顺序,将38例患者分为两组,对照组19例与观察组19例。对照组患者实施常规脑膜瘤切除术进行治疗,观察组患者实施显微镜下脑膜瘤切除术进行治疗,将两组间治疗结果进行对比。结果:对照组治疗总有效率为68.42%,观察组治疗总有效率为94.74%,对照组患者治疗总有效率明显低于观察组;两组患者治疗前GCS评分,无明显差异,P>0.05;观察组治疗后GCS评分,明显高于对照组,差异有统计学意义(P<0.05)。结论:在对中央回区脑膜瘤患者进行治疗时,应首先考虑应用显微镜下脑膜瘤切除术进行治疗,该方法能彻底将病灶清除,且对脑组织损伤较小,对患者预后康复有重要意义。Objective:To study the effect of microsurgical resection of meningiomas in the central gyrus.Methods:A total of 38 patients with meningiomas in the central gyrus were enrolled in this study from June 2017 to April 2018.According to the order of patients,38 patients were divided into two groups:Control group(19 cases)and experimental group(19 cases).The control group was treated with routine meningioma resection,the experimental group was treated with microscopic meningioma resection,and the results were compared between the two groups.Results:The total effective rate was 68.42%in the control group and 94.74%in the experimental group.The total effective rate in the control group was significantly lower than that in the experimental group.There was no significant difference in GCS score between the two groups before treatment,P>0.05;The GCS score of the experimental group was significantly higher than that of the control group(P<0.05).Conclusion:In clinical treatment of meningiomas in the central gyrus,microsurgical resection of meningiomas should be the first choice,which can completely remove the lesion and cause less damage to the brain tissue,it is of great significance to the prognosis and rehabilitation of patients.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3